
Arvinas Inc (ARVN) Stock Forecast & Price Target
Arvinas Inc (ARVN) Analyst Ratings
Bulls say
Arvinas is a leader in the emerging field of protein degradation, using its proprietary technology platform to develop novel therapeutics for oncology and neurology-related diseases. The company's PROteolysis TArgeting Chimera (PROTAC) technology allows for the targeted removal of disease-causing proteins by using the body's natural protein disposal system. With a strong pipeline of product candidates in various stages of development and positive clinical data, Arvinas has the potential for significant growth in the future. While there are standard risks associated with the biotechnology industry, the company's approach and progress thus far make it a promising investment opportunity.
Bears say
Arvinas is a clinical-stage biotechnology company with a promising protein degradation platform, but their current pipeline of therapeutics is still in early clinical stages and may not see full commercialization until 2029. Additionally, peak penetration of their upcoming drug, ARV-393, is only projected to reach 30%, and the company's revenue may be limited due to an 18% royalty sharing agreement for ex-US commercialization. Overall, while Arvinas shows potential, their current financials do not support a positive outlook at this time.
This aggregate rating is based on analysts' research of Arvinas Inc and is not a guaranteed prediction by Public.com or investment advice.
Arvinas Inc (ARVN) Analyst Forecast & Price Prediction
Start investing in Arvinas Inc (ARVN)
Order type
Buy in
Order amount
Est. shares
0 shares